Sangamo Therapeutics (SGMOQ) Payables (2010 - 2025)

Sangamo Therapeutics has reported Payables for 16 years, with the latest figure at $14.4 million in Q4 2025.

• On a quarterly basis, Payables fell 6.77% year-over-year to $14.4 million in Q4 2025; TTM through Dec 2025 was $14.4 million, a 6.77% decrease from a year earlier, with the FY2025 full-year figure at $14.4 million, down 6.77% from the prior year.
• Payables was $14.4 million for Q4 2025 at Sangamo Therapeutics, down from $15.6 million in the prior quarter.
• The five-year high for Payables was $22.4 million in Q4 2022, with the low at $8.0 million in Q3 2021.
• Average Payables over 5 years is $14.8 million, with a median of $15.4 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Payables sank 55.4% in 2021, then surged 129.72% in 2022.
• Over 5 years, Payables stood at $9.8 million in 2021, then soared by 129.72% to $22.4 million in 2022, then sank by 31.93% to $15.3 million in 2023, then increased by 1.48% to $15.5 million in 2024, then slipped by 6.77% to $14.4 million in 2025.
• The last three Payables figures came in at $14.4 million (Q4 2025), $15.6 million (Q3 2025), and $10.7 million (Q2 2025), per Business Quant data.